atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual...

Editor’s Choice Award 2021-Best Study on Psychedelics and Pharmacology

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of...

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products...

Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA)...

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic...

Editor’s Choice Award 2021-Best Study on Psychedelics and Nature

PT276 – Micah Haskell-Hoehl – Healing, Equity, and Federal Policy

Psychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS;...

Psychiatrist and Addiction Researcher, Dr. Henry Kranzler Joins Entheon Advisory Board

Load more